MyFinsight
Home
Blog
About
Proceeds from issuance of
common stock, net of...
$15,852K
Proceeds from issuance of
common shares upon...
$1,473K
Deferred offering costs
paid
-$10K
Underwritten offering
issuance costs paid
-$6K
Net cash provided by
(used in) financing...
$15,966K
(632.20%↑ Y/Y)
Canceled cashflow
$1,375K
Net decrease in cash
and cash...
-$167,813K
(-25.22%↓ Y/Y)
Canceled cashflow
$15,966K
Maturities of marketable
securities
$39,595K
(365.82%↑ Y/Y)
Stock-based compensation
expense
$4,269K
(-30.90%↓ Y/Y)
Accrued expenses and
other current...
$3,857K
(191.31%↑ Y/Y)
Accounts payable
$2,580K
(569.09%↑ Y/Y)
(gain) loss from
changes in fair value on...
$201K
(518.75%↑ Y/Y)
Accounts receivable
-$84K
(-113.93%↓ Y/Y)
Depreciation expense
$70K
(-26.32%↓ Y/Y)
Non-cash lease expense
$63K
(-44.25%↓ Y/Y)
Other assets
-$7K
(-133.33%↓ Y/Y)
Payment of term loan
final fee for loan...
$660K
Term loan principal
payments
$500K
(-83.33%↓ Y/Y)
Issuance costs paid on
at-the market offering
$215K
Net cash used in
investing activities
-$164,514K
(-75.71%↓ Y/Y)
Net cash used in
operating activities
-$19,260K
(48.41%↑ Y/Y)
Canceled cashflow
$39,595K
Canceled cashflow
$11,131K
Effect of changes in
exchange rate on cash and...
-$5K
(91.38%↑ Y/Y)
Purchases of marketable
securities
$203,781K
(100.68%↑ Y/Y)
Net loss
-$26,097K
(24.34%↑ Y/Y)
Purchase of property and
equipment
$328K
(-43.93%↓ Y/Y)
Prepaid expenses and
other current assets
$1,881K
(80.00%↑ Y/Y)
Deferred revenue
-$1,828K
(36.97%↑ Y/Y)
Accretion of net
investment discounts
$563K
Non-cash interest
expense
-$22K
(-115.71%↓ Y/Y)
Back
Back
Cash Flow
BioAge Labs, Inc. (BIOA)
BioAge Labs, Inc. (BIOA)
source: myfinsight.com